Budget Impact Analysis of Certolizumab Pegol in the Management of Patients With Moderate-To-Severe Active Rheumatoid Arthritis in Greece
Value Health
.
2014 Nov;17(7):A375.
doi: 10.1016/j.jval.2014.08.2585.
Epub 2014 Oct 26.
Authors
C Tzanetakos
1
,
N Maniadakis
1
,
G Kourlaba
2
,
A Tzioufas
3
,
A Goules
3
,
T Theodoratou
4
,
P Christou
4
Affiliations
1
National School of Public Health, Athens, Greece.
2
Collaborative Center for Clinical Epidemiology and Outcomes Research (CLEO), Athens, Greece.
3
Athens Medical School, Athens, Greece.
4
UCB Pharma, Athens, Greece.
PMID:
27200816
DOI:
10.1016/j.jval.2014.08.2585
No abstract available